These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38951814)

  • 1. Differences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG.
    Wieczorek L; Chang D; Sanders-Buell E; Zemil M; Martinez E; Schoen J; Chenine AL; Molnar S; Barrows B; Poltavee K; Charurat ME; Abimiku A; Blattner W; Iroezindu M; Kokogho A; Michael NL; Crowell TA; Ake JA; Tovanabutra S; Polonis VR;
    Virol J; 2024 Jun; 21(1):148. PubMed ID: 38951814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.
    Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparisons of the genetic and neutralization properties of HIV-1 subtype C and CRF07/08_BC env molecular clones isolated from infections in China.
    Wang S; Nie J; Wang Y
    Virus Res; 2011 Jan; 155(1):137-46. PubMed ID: 20875470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broad antibody mediated cross-neutralization and preclinical immunogenicity of new codon-optimized HIV-1 clade CRF02_AG and G primary isolates.
    Agwale SM; Forbi JC; Notka F; Wrin T; Wild J; Wagner R; Wolf H
    PLoS One; 2011; 6(8):e23233. PubMed ID: 21829720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.
    Dieltjens T; Heyndrickx L; Willems B; Gray E; Van Nieuwenhove L; Grupping K; Vanham G; Janssens W
    Retrovirology; 2009 Dec; 6():113. PubMed ID: 20003438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.
    Hraber P; Rademeyer C; Williamson C; Seaman MS; Gottardo R; Tang H; Greene K; Gao H; LaBranche C; Mascola JR; Morris L; Montefiori DC; Korber B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies.
    Hraber P; Korber BT; Lapedes AS; Bailer RT; Seaman MS; Gao H; Greene KM; McCutchan F; Williamson C; Kim JH; Tovanabutra S; Hahn BH; Swanstrom R; Thomson MM; Gao F; Harris L; Giorgi E; Hengartner N; Bhattacharya T; Mascola JR; Montefiori DC
    J Virol; 2014 Nov; 88(21):12623-43. PubMed ID: 25142591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of mutations in V3/C3 domain with enhanced sensitivity of HIV-1 clade C primary envelopes to autologous broadly neutralizing plasma antibodies.
    Deshpande S; Patil S; Kumar R; Shrivastava T; Srikrishnan AK; Murugavel KG; Koff WC; Chakrabarti BK; Bhattacharya J
    Retrovirology; 2016 Jun; 13(1):41. PubMed ID: 27307004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response.
    Shrivastava T; Samal S; Tyagi AK; Goswami S; Kumar N; Ozorowski G; Ward AB; Chakrabarti BK
    Vaccine; 2018 Mar; 36(12):1627-1636. PubMed ID: 29429810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.
    deCamp A; Hraber P; Bailer RT; Seaman MS; Ochsenbauer C; Kappes J; Gottardo R; Edlefsen P; Self S; Tang H; Greene K; Gao H; Daniell X; Sarzotti-Kelsoe M; Gorny MK; Zolla-Pazner S; LaBranche CC; Mascola JR; Korber BT; Montefiori DC
    J Virol; 2014 Mar; 88(5):2489-507. PubMed ID: 24352443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refined identification of neutralization-resistant HIV-1 CRF02_AG viruses.
    Jacob RA; Abrahams F; Tongo M; Schomaker M; Roux P; Mpoudi Ngole E; Burgers WA; Dorfman JR
    J Virol; 2012 Jul; 86(14):7699-703. PubMed ID: 22573859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
    Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the genotypic and phenotypic properties of HIV-1 standard subtype B and subtype B/B' env molecular clones derived from infections in China.
    Xie H; Nie J; Chen Q; Huang W; Wang Y
    Emerg Microbes Infect; 2018 May; 7(1):90. PubMed ID: 29769530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
    Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic characteristics, coreceptor usage potential and evolution of Nigerian HIV-1 subtype G and CRF02_AG isolates.
    Ajoge HO; Gordon ML; de Oliveira T; Green TN; Ibrahim S; Shittu OS; Olonitola SO; Ahmad AA; Ndung'u T
    PLoS One; 2011 Mar; 6(3):e17865. PubMed ID: 21423811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection.
    Ndlovu B; Gounder K; Muema D; Raju N; Hermanus T; Mthethwa Q; Robertson K; Walker BD; Georgiev IS; Morris L; Moore PL; Ndung'u T
    Virology; 2020 Jul; 546():1-12. PubMed ID: 32275203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-Neutralizing Antibodies in HIV-1 Individuals Infected by Subtypes B, F1, C or the B/Bbr Variant in Relation to the Genetics and Biochemical Characteristics of the env Gene.
    de Almeida DV; Macieira KV; Grinsztejn BG; Veloso Dos Santos VG; Guimarães ML
    PLoS One; 2016; 11(12):e0167690. PubMed ID: 27936047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-neutralizing antibody profile of Chinese HIV-1-infected individuals and the viral envelope features from elite neutralizers.
    Ren C; Liu S; Li Y; Zhuang M; Yu H; Wang J; Sun F; Li D; Zhang H; Liu W; Liang S; Zhong P; Ling H
    J Acquir Immune Defic Syndr; 2014 Dec; 67(5):472-80. PubMed ID: 25202919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significant contribution of subtype G to HIV-1 genetic complexity in Nigeria identified by a newly developed subtyping assay specific for subtype G and CRF02_AG.
    Heipertz RA; Ayemoba O; Sanders-Buell E; Poltavee K; Pham P; Kijak GH; Lei E; Bose M; Howell S; O'Sullivan AM; Bates A; Cervenka T; Kuroiwa J; Akintunde A; Ibezim O; Alabi A; Okoye O; Manak M; Malia J; Peel S; Maisaka M; Singer D; O'Connell RJ; Robb ML; Kim JH; Michael NL; Njoku O; Tovanabutra S
    Medicine (Baltimore); 2016 Aug; 95(32):e4346. PubMed ID: 27512845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.